MSDx: Company Presentation
MSDx, Inc.provides novel biomarker tools for studying disease processes. The company is focused on commercializing both Research Use Only (RUO) and In VitroDiagnostic (IVD) blood test products that will be used in monitoring neurological, autoimmune, and inflammatory disorders.
Arbsource was founded to transform wastewater treatment from a costly energy liability into a valuable resource through state-of-the-art microbial electrochemical cell technologies. Our team includes domain experts in the water industry passionate about contributing to a safe, secure, and sustainable water infrastructure with our award-winning Arbcell biotechnology.
Company Presentation: NuvOx
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.
Yulex moves into the AZBio Fast Lane
http://www.yulex.com/ Rubber and commerce go hand in hand and rubber products are everywhere. Yulex Corporation is the global leader in guayule-based biomaterials for a wide range of markets and diverse applications. Yulex’s Guayule BioRubber Emulsions and BioRubber Solids have medical, consumer, and industrial applications to grow an increasingly diverse market community with ultra-pure, high-performance products. From medical devices to fabric coatings, and from bedding to industrial packaging adhesives, Yulex also provides technical and product development guidance and support, and even custom material compounding and formulation.
Yulex Corporation, a technology, marketing and biomaterial product development company that applies sustainable crop science, clean bioprocessing, and materials science for the production of natural, allergy-friendly BioRubber derived from the renewable, crop Guayule was honored with the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association
DNA on a Shirt
DNA on a SHIRT is an innovative, unique company that created wearable and wallable™ genetic art that couples art and science, meshing fashion and education in the process. Through their various DNA inspired T-shirts and art prints, our mission is to create a catalyst for engagement by engaging art, science and people. Our products include art pieces and T-shirts that showcase the DNA fingerprint of people, pets, plants and zoo animals.
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc
Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership.Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients.In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.